2025 Poster Presentations
P311: THE ROLE OF P16 EXPRESSION IN RESPONSE TO INDUCTION CHEMOTHERAPY IN SINONASAL MALIGNANCIES
Joseph Lee, MD; Mohammad Bilal Alsavaf; Matthew Marquardt; Eric Nisenbaum, MD; Ricardo Carrau, MD; Kyle VanKoevering, MD; The Ohio State University Department of Otolaryngology
Background: Patients with p16-positive oropharyngeal squamous cell carcinoma tend to have an overall better prognosis and response to systemic treatment compared to those with p16-negative oropharyngeal carcinoma. However, the role and impact of p16 expression in sinonasal carcinoma remains unclear. The purpose of this study was to characterize and compare the response to induction chemotherapy (IC) among advanced stage sinonasal carcinoma accounting for p16 expression.
Methods: Retrospective chart review was performed among treatment naïve adult patients who received induction chemotherapy for sinonasal carcinoma at a single institution between July 2010 and February 2019. Patients without p16 testing performed on pathology were excluded. Pre and post-imaging studies were evaluated and tumor volume measured according to the RECIST1.1 guidelines to evaluate for tumor response to IC. Progression free survival rates were also calculated using Kaplan-Meier survival curve. Categorical comparisons were made using a Chi-square test.
Results: 19 patients with advanced sinonasal carcinomas who underwent induction chemotherapy were included in this study. There was no statistical difference in response to induction chemotherapy between patients with p16 positive and p16 negative sinonasal carcinoma (62.5% with a favorable response vs 72.7% respectively, p=0.912). There was no statistically significant difference in progression free survival among patients with p16+ tumors and p16- tumors (median = 18.9 months vs 11.7 months respectively, p=0.3, see Figure 1 for Kaplan-Meier Survival Curve). 36% of p16 negative tumors were noted to have dural involvement compared to 87.5% of p16 positive tumors (p=0.059).
Conclusions: P16 expression does not appear to be a prognostic indicator for overall response to induction chemotherapy in sinonasal carcinoma. Furthermore, p16 expression did not significantly impact overall progression free survival in this study. A larger patient cohort is necessary to further elucidate the prognostic implications, if any, of p16 expression in patients with sinonasal carcinoma.
